CN104402919A - 一种合成手性频那醇硼酯化合物的方法 - Google Patents
一种合成手性频那醇硼酯化合物的方法 Download PDFInfo
- Publication number
- CN104402919A CN104402919A CN201410566747.3A CN201410566747A CN104402919A CN 104402919 A CN104402919 A CN 104402919A CN 201410566747 A CN201410566747 A CN 201410566747A CN 104402919 A CN104402919 A CN 104402919A
- Authority
- CN
- China
- Prior art keywords
- pinacol
- synthesis
- boron ester
- ester cpds
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 title claims abstract description 69
- -1 pinacol boron ester compound Chemical class 0.000 title claims abstract description 61
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 26
- 150000001336 alkenes Chemical class 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229910000085 borane Inorganic materials 0.000 claims description 19
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000010189 synthetic method Methods 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 229910052723 transition metal Inorganic materials 0.000 abstract description 4
- 150000003624 transition metals Chemical class 0.000 abstract description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 3
- 229910052763 palladium Inorganic materials 0.000 abstract description 3
- 229910052703 rhodium Inorganic materials 0.000 abstract description 3
- 239000010948 rhodium Substances 0.000 abstract description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052707 ruthenium Inorganic materials 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract description 2
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 abstract 1
- 229910000033 sodium borohydride Inorganic materials 0.000 abstract 1
- 239000012279 sodium borohydride Substances 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000004607 11B NMR spectroscopy Methods 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000006555 catalytic reaction Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006197 hydroboration reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 0 CC1(C)OB(CC(*)*)OC1(C)C Chemical compound CC1(C)OB(CC(*)*)OC1(C)C 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- FOZROJWWZAQVDD-NSHDSACASA-N 2-[(2S)-2-(3-fluorophenyl)propyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound B1(OC(C(O1)(C)C)(C)C)C[C@H](C)C2=CC(=CC=C2)F FOZROJWWZAQVDD-NSHDSACASA-N 0.000 description 1
- RTZVYWDKHPDDDT-NSHDSACASA-N 2-[(2S)-2-(4-bromophenyl)propyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C[C@@H](CB1OC(C)(C)C(C)(C)O1)c1ccc(Br)cc1 RTZVYWDKHPDDDT-NSHDSACASA-N 0.000 description 1
- OOXHOIYQZGJZPO-NSHDSACASA-N 2-[(2S)-2-(4-chlorophenyl)propyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound B1(OC(C(O1)(C)C)(C)C)C[C@H](C)C2=CC=C(C=C2)Cl OOXHOIYQZGJZPO-NSHDSACASA-N 0.000 description 1
- GHDDEWJBDCPXIV-NSHDSACASA-N 2-[(2S)-2-(4-fluorophenyl)propyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound B1(OC(C(O1)(C)C)(C)C)C[C@H](C)C2=CC=C(C=C2)F GHDDEWJBDCPXIV-NSHDSACASA-N 0.000 description 1
- VLXIDYTVGAIIPE-LBPRGKRZSA-N 2-[(2S)-2-(4-methoxyphenyl)propyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=CC=C(C=C1)[C@H](CB1OC(C(O1)(C)C)(C)C)C VLXIDYTVGAIIPE-LBPRGKRZSA-N 0.000 description 1
- UVIMCFJEHBAQLC-CQSZACIVSA-N 4,4,5,5-tetramethyl-2-[(2S)-2-methyl-4-phenylbutyl]-1,3,2-dioxaborolane Chemical compound CC1(OB(OC1(C)C)C[C@@H](CCC1=CC=CC=C1)C)C UVIMCFJEHBAQLC-CQSZACIVSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- UDLLFLQFQMACJB-UHFFFAOYSA-N azidomethylbenzene Chemical compound [N-]=[N+]=NCC1=CC=CC=C1 UDLLFLQFQMACJB-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical compound [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本方法公开了一种合成手性频那醇硼酯化合物的方法,以烯烃和频那醇硼烷为原料,以手性FeX2-IPO络合物为催化剂,在三乙基硼氢化钠存在下,反应3分钟-48小时制得频那醇硼酯化合物;与现有方法相比,该方法适用于多种不同类型的烯烃,反应条件温和,操作简便,原子经济性高。另外,反应无需其他任何的有毒过渡金属(如钌、铑、钯等)盐类的加入,在药物合成上具有较大的实际应用价值。且反应的产率也较好,一般为75%~98%,对映体选择性也较高,一般为80%~99%。
Description
技术领域
本方法涉及一种合成手性频那醇硼酯化合物的方法,尤其是涉及一种光学活性的频那醇硼酯化合物的合成方法。
背景技术
近年来,过渡金属催化的反应在材料、化工、药物领域得到了广泛的应用,但是由于金属残留的问题,过渡金属催化剂尤其在药物领域有着诸多的限制,而铁催化的反应就可以避免有毒重金属残留的问题,因此发展高效的铁催化的反应对于药物合成领域有重大的意义。
烯烃的硼氢化反应自1956年被Herbert Charles Brown发现以来被广泛的应用于有机合成领域[(a)Brown,H.C.J.Am.Chem.Soc.1956,78,5694,(b)Blair,D.J.;Fletcher,C.J.;Wheelhouse,K.M.P.;Aggarwal,V.K.Angew.Chem.2014,126,5658]。然而,如何高效制备手性的硼试剂一直是有机化学领域研究的热点与难点,传统方法需要使用当量的手性试剂(Brown,H.C.Acc.Chem.Res.1988,21,287.),近年来发展的过渡金属催化烯烃的不对称硼氢化反应又有着有毒重金属残留和对映体选择性不高(小于90%)的问题[(a)Mazet,C.;Gerard,D.Chem.Commun.2011,47,298;(b)Corberan,R.;Mszar,N.W.;Hoveyda,A.H.Angew.Chem.Int.Ed.2011,50,7079]。因此,发展高效率高选择性的铁催化的烯烃的硼氢化反应合成手性硼化合物有着重大的意义,尤其在药物领域有广阔的应用前景。
发明内容
本发明要解决的问题是提供一种有效的合成频那醇硼酯化合物的方法,是由手性FeX2-IPO络合物催化烯烃和频那醇硼烷的硼氢化反应,高效率高对映体选择性地合成光学活性的频那醇硼酯化合物的方法。
本发明是通过以下技术方案来实现的:
本发明一种合成手性频那醇硼酯化合物的方法,以烯烃和频那醇硼烷为原料,以手性FeX2-IPO络合物为催化剂,在三乙基硼氢化钠存在下,反应3分钟-48 小时制得频那醇硼酯化合物,烯烃、频那醇硼烷、FeX2-IPO络合物、三乙基硼氢化钠的摩尔比为1:0.1-10:0.0005-0.05:0.0015-0.15;
所述的烯烃的结构式为R1≠R2;
所述的频那醇硼烷的结构式为
其中,R1,R2任选自包括环烷基在内的C1-C16的烷基、取代的芳基 其中R3,R4,R5,R6,R7任选自H、卤素、C1-C16的烷基、C1-C16的烃氧基,烃硫基中的任意一种,X为F、Cl、Br、I、OAc、CF3SO3中的任意一种。
作为进一步地改进,本发明所述的FeX2-IPO络合物为手性络合物,所述的产物频那醇硼酯化合物为光学活性的,其结构式为其中*代表手性碳原子R1,R2任选自包括环烷基在内的C1-C16的烷基、取代的芳基
作为进一步地改进,本发明所述的FeX2-IPO络合物的结构式为光学纯的如下化合物或其对映体或消旋体,R8任选自C1-C16的烃基、萘基、取代的芳基,苄基:
X为F、Cl、Br、I、OAc、CF3SO3中的任意一种。
作为进一步地改进,本发明所述的所述合成方法中有有机溶剂的参与,所述的有机溶剂是苯、四氯化碳、甲苯、四氢呋喃、乙醚、二氯甲烷、乙腈、二氧六环、石油醚、环己烷、正己烷、乙酸乙酯、三氯甲烷、N,N-二甲酰胺中的任意一种。
作为进一步地改进,本发明所述的所述合成方法中不加任何溶剂。
作为进一步地改进,本发明所述的所述的烯烃、频那醇硼烷、FeX2-IPO络合物、三乙基硼氢化钠的摩尔比为1:0.5-2:0.005-0.05:0.015-0.15。
作为进一步地改进,本发明所述的所述合成方法中,反应温度为-30℃~80℃。
作为进一步地改进所得的产物是经过重结晶、薄层层析、柱层析或减压蒸馏加以分离而成。
本发明方法提供了一种有效的由FeX2-IPO络合物尤其是手性FeX2-IPO络合物为催化剂,由烯烃和频那醇硼烷高效率高对映体选择性的合成光学活性的频那醇硼酯化合物的方法。与现有方法相比,该方法适用于多种不同类型的烯烃,反应条件温和,操作简便,原子经济性高。另外,反应无需其他任何的有毒过渡金属(如钌、铑、钯等)盐类的加入,在药物合成上具有较大的实际应用价值。且反应的产率也较好,一般为75%~98%,对映体选择性也较高,一般为80%~99%。
具体实施方式
本发明的方法是一种有效的有烯烃和频那醇硼烷合成频那醇硼酯化合物的方法。该方法是用FeX2-IPO络合物作为催化剂。尤其是以手性的FeX2-IPO络合物作为催化剂时能够由烯烃和频那醇硼烷高效率高对映体选择性的合成光学活性的频那醇硼酯化合物。
本发明方法所合成的频那醇硼酯化合物的分子通式是:当使用手性FeX2-IPO络合物作为催化剂时,所合成的频那醇硼酯化合物是光学活性的,其通式是其中*代表手性碳原子。R1,R2任选自包括环 烷基在内的C1-C16的烃基、萘基、取代的芳基其中R3,R4,R5,R6,R7任选自H、卤素、C1-C16的烷基、C1-C16的烃氧基,胺基或取代芳基。上述的卤素包括F、Cl、Br或I,上述的烃基可以是烷基,环烷基,苄基。
本发明的频那醇硼酯化合物是以烯烃和频那醇硼烷为原料,在三乙基硼氢化钠存在下,在有机溶剂中或无需溶剂,以FeX2-IPO络合物尤其是以FeX2-IPO络合物作为催化剂反应制得的,可用下式表示:
烯烃的结构式为:其中,R1,R2如前所述;频那醇硼烷结构式为 催化剂的结构通式为(为任意光学纯的结构、或其对映体或消旋体,不受以下结构式所限)
R8任选自C1-C16的烃基、萘基、取代的芳基,苄基。
所述的烯烃、频那醇硼烷、FeCl2-IPO络合物、三乙基硼氢化钠的摩尔比为1:0.1-10:0.0005-0.05:0.0015-0.15,进一步1:0.5-2:0.005-0.05:0.015-0.15;尤其推荐反应的摩尔比为:烯烃、频那醇硼烷、FeCl2-IPO络合物、三乙基硼氢化钠的摩尔比为1:1:0.005:0.015。反应温度推荐为-30℃~80℃,进一步推荐-10℃~60℃,尤其推荐25℃。反应时间推荐为3分钟-48小时,进一步推荐30分钟-12小时,尤其推荐1小时。其中,R1,R2,R3,R4,R5,R6,R7,R8如前所述。
本发明中提到的烷基,均推荐碳数为1~16的基团,进一步推荐碳数为1~10,尤其推荐碳数为1~6的。本发明提到的环烷基,均推荐碳数为3~16的基 团,进一步推荐碳数为3~10,尤其推荐碳数为3~6的。本发明提到的芳基,均指苯基、萘基和含N,O,S的杂芳基。
本发明方法的反应可以在无溶剂下进行,也可以在在极性或非极性溶剂中进行,如苯、四氯化碳、甲苯、四氢呋喃、乙醚、二氯甲烷、乙腈、二氧六环、石油醚、环己烷、正己烷、乙酸乙酯、三氯甲烷、N,N-二甲酰胺等。
本发明方法可以通过重结晶、薄层层析、柱层析或减压蒸馏加以分离。本发明方法提供了一些新的频那醇硼酯化合物其中例如R1为4-异丁基苯基、2-(6-甲氧基)萘基、3-氟-4-苯基-苯基、3-苯氧基苯基、3-苯甲酰基苯基,R2为甲基时。该类化合物可以经常柜的反应氧化成相应的丙酸类药物:布洛芬、萘普生、氟比洛芬、非诺洛芬、酮洛芬,当使用的催化剂为手性的FeCl2-IPO络合物时,反应产率较高,在90%以上,对映体选择性也较高,在98%以上,同时本方法的反应无需加入其他任何的有毒过渡金属(如钌、铑、钯等)盐类的加入,因此在药物合成上具有较大的实际应用价值。
下面通过具体实施例对本发明的技术方案作进一步地具体说明:
实施例1:手性FeX2-IPO络合物催化的烯烃和频那醇硼烷的硼氢化反应
-30℃下,在一干燥的反应试管中加入(手性)FeX2-IPO络合物(0.025mmol),烯烃(0.5mmol),频那醇硼烷(0.5mmol),乙醚(1mL),三乙基硼氢化钠(0.05mmol),然后在室温下搅拌1小时后柱层析分离得到产物。
P1:(S)-(+)-4,4,5,5-四甲基-2-(2-苯基丙基)-1,3,2-dioxaborolane.
(S)-(+)-4,4,5,5-tetramethyl-2-(2-propyl)-1,3,2-dioxaborolane
(或其对映体)
油状液体,98%产率,[α]20 D=+21.9(c1.0,CHCl3),96.1%ee,HPLC conditions:Chiralcel OD-H,n-hexane/i-PrOH=99/1,0.25mL/min,n=254nm,tr16.7(minor),18.0(major);IR(neat):2978,1453,1370,1323,1146cm-1;1H NMR(CDCl3,400MHz):δ7.28-7.21(m,4H),7.16-7.11(m,1H),3.08-2.98(m,1H),1.27(d,J=6.8Hz,3H),1.17-1.13(m,14H);13C NMR(CDCl3,100MHz):δ149.1,128.1,126.5,125.6, 82.8,35.7,24.8,24.7,24.6.11B NMR(CDCl3,128MHz):δ33.7;HRMS(EI)calculated for[C15H23BO2]+requires m/z246.1791,found m/z246.1791.
P2:(S)-(+)-4,4,5,5-tetramethyl-2-(2-(p-tolyl)propyl)-1,3,2-dioxaborolane
油状液体,93%产率,[α]20 D=+24.9(c0.97,CHCl3),98.3%ee;1H NMR(CDCl3,400MHz):δ7.05(d,J=8.4Hz,2H),6.99(d,J=8.4Hz,2H),2.97-2.87(m,1H),2.22(s,3H),1.18(d,J=6.8Hz,3H),1.10-1.03(m,14H);13C NMR:(100.6MHz,CDCl3):δ146.2,134.9,128.8,126.4,82.9,35.3,24.8,24.7,24.6,21.4,20.9;11B NMR(CDCl3,128MHz):δ33.7;HRMS(EI)calculated for[C16H25BO2]+requires m/z260.1948,found m/z260.1951.
P3:(S)-2-(2-(4-isobutylphenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
油状液体,77%产率,[α]20 D=+19.1(c1.0,CHCl3),98.9%ee,;1H NMR(CDCl3,400.1MHz):δ7.13(d,J=7.6Hz,2H),7.03(d,J=7.6Hz,2H),3.00(m,1H),2.42(d,J=7.2Hz,2H),1.89-1.75(m,1H),1.26(d,J=7.0Hz,3H),1.20-1.08(m,14H),0.88(d,J=6.6Hz,6H);13C NMR:(100.6MHz,CDCl3):δ146.3,138.9,128.9,126.3,82.9,45.0,35.4,30.2,25.0,24.7,24.6,22.4,22.3;HRMS(EI)calculated for[C19H31BO2]+requires m/z302.2417,found m/z302.2422.
P4 :
(S)-(+)-2-(2-(4-methoxyphenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
油状液体,90%产率,[α]20 D=+22.7(c0.98,CHCl3),96.1%ee,1H NMR(CDCl3,400MHz):δ7.15(d,J=8.4Hz,2H),6.80(d,J=8.4Hz,2H),3.76(s,3H),3.04-2.94(m,1H),1.24(d,J=6.8Hz,3H),1.16-1.10(m,14H).13C NMR(100.6MHz,CDCl3):δ157.5,141.4,127.4,113.5,82.9,55.1,34.9,25.1,24.7,24.6,21.4; 11B NMR(CDCl3,128MHz):δ33.9;HRMS(EI)calculated for[C16H25BO3]+requires m/z276.1897,found m/z276.1890.
P5:
(S)-(+)-triisopropyl(4-(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)phenoxy)silane
油状液体,88%产率,[α]20 D=+20.0(c0.97,CHCl3),99%ee,1H NMR(CDCl3,400MHz):δ7.09-7.04(m,2H),6.79-6.74(m,2H),3.02-2.91(m,1H),1.30-1.19(m,6H),1.14(d,J=2.0Hz,12H),1.12-1.04(m,20H);13CNMR(100.6MHz,CDCl3):δ153.8,141.6,127.3,119.4,82.9,35.1,25.4,24.7,21.4,17.9,12.7;11B NMR(CDCl3,128MHz):δ33.7;HRMS(EI)calculated for[C24H43BO4Si]+requires m/z418.3075,found m/z418.3074.
P6 :
(S)-(+)-N,N-dimethyl-4-(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)aniline
油状液体,72%产率,[α]20 D=+28.9(c0.98,CHCl3),95.9%ee,1H NMR(CDCl3,400MHz):δ7.12(d,J=8.6Hz,2H),6.69(d,J=8.6Hz,2H),3.01-2.88(m,7H),1.24(d,J=7.2Hz,3H),1.18-1.06(m,14H);13C NMR(100.6MHz,CDCl3):δ149.0,137.9,127.1,113.0,82.9,41.0,34.7,25.0,24.8,24.7,21.3;11B NMR(CDCl3,128 MHz):δ34.0;HRMS(EI)calculated for[C17H28BNO2]+requires m/z289.2213,found m/z289.2219.
P7 :
(S)-(+)-4,4,5,5-tetramethyl-2-(2-(4-(methylthio)phenyl)propyl)-1,3,2-dioxaborola ne
油状液体,90%产率,[α]20 D=+34.5(c1.0,CHCl3),97.7%ee,1H NMR(CDCl3,400MHz):δ7.21-7.14(m,4H),3.05-2.94(m,1H),2.45(s,3H),1.25(d,J=6.8Hz,3H),1.17-1.10(m,14H);13C NMR(100.6MHz,CDCl3):δ146.6,134.9,127.23,127.17,83.0,35.3,24.74,24.67,20.9,16.5;11B NMR(CDCl3,128MHz):δ33.6;HRMS(EI)calculated for[C16H25BO2S]+requires m/z292.1668,found m/z292.1672.
P8:(S)-(+)-tert-butyldimethyl((4-(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-2-yl)benzyl)oxy)silane
油状液体,92%产率,[α]20 D=+19.1(c0.99,CHCl3),95.1%ee,1H NMR(CDCl3,400MHz):δ7.23-7.17(m,4H),4.69(s,2H),3.07-2.97(m,1H),1.26(d,J=6.8Hz,3H),1.17-1.12(m,14H),0.93(s,9H),0.08(s,6H);13C NMR(100.6MHz,CDCl3):δ147.9,138.7,126.4,126.0,83.0,64.9,35.5,26.0,24.9,24.8,24.7,21.3,18.4,-5.2; 11B NMR(CDCl3,128MHz):δ34.0;HRMS(EI)calculated for[C22H39BO3Si]+requires m/z390.2762,found m/z390.2763.
P9 :
(S)-(+)-2-(2-(4-fluorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
油状液体,92%产率,[α]20 D=+21.8(c1.0,CHCl3),95.3%ee,1H NMR(CDCl3,400MHz):δ7.20-7.16(m,2H),6.97-6.91(m,2H),3.07-2.97(m,1H),1.25(d,J=7.2Hz,3H),1.15-1.11(m,14H);13C NMR(CDCl3,100.6MHz):δ161.0(d,J=241.4Hz),144.7(d,J=2.9Hz),127.9(d,J=8.0Hz),114.7(d,J=20.4Hz),83.0,35.1,25.1,24.7,24.6,21.3;11B NMR(CDCl3,128MHz):δ33.8;19F NMR(CDCl3,376MHz):δ-118.2;HRMS(EI)calculated for[C15H22BFO2]+requires m/z264.1697,found m/z264.1693.
(S)-2-(2-(4-chlorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
[α]20 D=+26.9(c0.99,CHCl3),94.9%ee,1H NMR(CDCl3,400.1MHz):δ7.22(d,J=8.2Hz,2H),7.16(d,J=8.2Hz,2H),3.07-2.94(m,1H),1.24(d,J=6.8Hz,3H),1.20-1.08(m,14H);13C NMR:(100.6MHz,CDCl3):δ147.6,131.1,128.2,128.0,83.0,35.2,24.8,24.71,24.67;11B NMR:(128MHz,CDCl3):δ33.3;HRMS(EI)calculated for[C15H22BClO2]+requires m/z280.1401,found m/z280.1399.
(S)-2-(2-(4-bromophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
[α]20 D=+27.5(c0.99,CHCl3),94.9%ee,1H NMR:(400.1MHz,CDCl3):δ7.37(d,J=8.4Hz,2H),7.11(d,J=8.4Hz,2H),3.06-2.93(m,1H),1.24(d,J=6.8Hz,3H),1.21-1.09(m,14H);13C NMR:(100.6MHz,CDCl3):δ148.2,131.1,128.4,119.2,83.0,77.3,77.0,76.7,35.3,24.7,24.7,24.7;HRMS(EI)calculated for[C15H22BBrO2]+requires m/z324.0896,found m/z324.0900.
(S)-(+)-2-(2-(3-fluorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan e
[α]20 D=+20.7(c0.99,CHCl3),98.1%ee,1H NMR(CDCl3,400MHz):δ7.24-7.17(m,1H),7.00(d,J=7.6Hz,1H),6.94(d,J=10.4Hz,1H),6.86-6.80(m,1H),3.08-2.98(m,1H),1.26(d,J=7.2Hz,3H),1.17-1.11(m,14H);13C NMR(CDCl3,100MHz):δ162.9(d,J=242.8),152.0(d,J=6.6Hz),129.5(d,J=8.1Hz),122.3(d,J=2.2Hz),113.5(d,J=20.4Hz),112.4(d,J=21.2Hz),83.0,35.6,24.73,24.68,24.6,20.9;11B NMR(CDCl3,128MHz):δ33.7;19FNMR(CDCl3,376MHz):δ-114.1;HRMS(EI)calculated for[C15H22BFO2]+requires m/z264.1697,found m/z264.1701.
(S)-(+)-2-(2-(2-fluorophenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan e
[α]20 D=+13.4(c1.0,CHCl3),83.9%ee,1H NMR(CDCl3,400MHz):δ7.28-7.22(m,1H),7.15-7.09(m,1H),7.07-7.02(m,1H),6.99-6.93(m,1H),3.41-3.31(m,1H),1.28(d,J=7.2Hz,3H),1.20-1.14(m,14H);13C NMR(CDCl3,100MHz):δ160.5(d,J=242.8Hz),135.6(d,J=14.6Hz),127.7(d,J=5.1Hz),127.0(d,J=8.1Hz),123.8(d,J=2.9Hz),115.1(d,J=22.6Hz),83.0,28.8,24.7,24.6,23.5,19.5;11B NMR(CDCl3,128MHz):δ33.7;19F NMR(CDCl3,376MHz):δ-118.7;HRMS(EI)calculated for[C15H22BFO2]+requires m/z264.1697,found m/z264.1695.
(S)-(+)-4,4,5,5-tetramethyl-2-(2-(3-(trifluoromethyl)phenyl)propyl)-1,3,2-dioxab orolane
[α]20 D=+17.6(c1.0,CHCl3),91.7%ee),96.5%ee,1H NMR(CDCl3,400MHz):δ7.50(s,1H),7.44-7.34(m,3H),3.15-3.05(m,1H),1.30(d,J=6.8Hz,3H),1.18-1.13(m,14H);13C NMR(CDCl3,100MHz):δ150.0,130.3(q,J=31.6Hz),130.0,128.6,124.4(q,J=270.5Hz),123.7(q,J=3.7Hz),122.5(q,J=4.2Hz),83.1,35.7,24.7,24.6,20.9;11B NMR(CDCl3,128MHz):δ33.5;19F NMR(CDCl3,376MHz):δ-62.5;HRMS(EI)calculated for[C16H22BF3O2]+requires m/z314.1665,found m/z314.1664.
(S)-2-(2-(3-bromo-4-methoxyphenyl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborol ane
[α]20 D=+21.6(c0.98,CHCl3),96.5%ee,1H NMR:(400.1MHz,CDCl3):δ7.42(d,J=2.0Hz,1H),7.13(dd,J=8.4,2.0Hz,1H),6.81(d,J=8.4Hz,1H),3.86(s,3H),3.03-2.91(m,1H),1.24(d,J=6.8Hz,3H),1.21-1.07(m,14H);13C NMR:(100.6MHz,CDCl3):δ153.8,143.0,131.7,126.4,111.8,111.2,83.0,56.3,34.8,24.8,24.74,24.71;HRMS(EI)calculated for[C16H24BBrO3]+requires m/z354.1002,found m/z354.1004.
(S)-(+)-4,4,5,5-tetramethyl-2-(2-(naphthalen-2-yl)propyl)-1,3,2-dioxaborolane
[α]20 D=+26.7(c1.0,CHCl3),98.3%ee,1H NMR(CDCl3,400MHz):δ7.78-7.73(m,3H),7.65(s,1H),7.44-7.36(m,3H),3.26-3.16(m,1H),1.36(d,J =6.8Hz,3H),1.27-1.22(m,2H),1.13(s,12H);13C NMR(CDCl3,100.6MHz):δ146.7,133.6,132.1,127.7,127.54,127.49,125.8,125.6,124.9,124.4,83.0,35.8,24.73,24.71,24.68,20.9;11B NMR(CDCl3,128MHz):δ33.6;HRMS(EI)calculated for[C19H25BO2]+requires m/z296.1948,found m/z296.1959.
(S)-2-(2-(6-methoxynaphthalen-2-yl)propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborol ane.
[α]20 D=+32.7(c1.05,CHCl3),97.5%ee,1H NMR:(400.1MHz,CDCl3):δ7.70-7.62(m,2H),7.58(s,sH),7.36(d,J=8.4Hz,1H),7.15-7.05(m,2H),3.88(s,3H),3.24-3.11(m,1H),1.34(d,J=6.8Hz,3H),1.26-1.19(m,2H),1.13(s,12H); 13C NMR:(100.6MHz,CDCl3):δ157.0,144.4,133.0,129.0(2C),126.6,126.3,124.3,118.4,105.6,83.0,55.2,35.7,24.8,24.74,24.68;11B NMR:(128MHz,CDCl3):δ33.7;HRMS(EI)calculated for[C20H27BO3]+requires m/z326.2053,found m/z326.2052.
(R)-(+)-4,4,5,5-tetramethyl-2-(2-phenylbutyl)-1,3,2-dioxaborolane(7p).
[α]20 D=+13.9(c0.97,CHCl3),98.5%ee,1H NMR(CDCl3,400MHz):δ7.27-7.22(m,2H),7.20-7.17(m,2H),7.16-7.10(m,1H),2.77-2.69(m,1H),1.70-1.52(m,2H),1.26-1.18(m,1H),1.14-1.08(m,13H),0.77(t,J=7.4Hz,3H);13C NMR(CDCl3,100.6MHz):δ147.2,128.0,127.5,125.6,82.8,43.2,32.2,24.63,24.60,19.2,12.2;11B NMR(CDCl3,128MHz):δ33.8;HRMS(EI)calculated for[C16H25BO2]+requires m/z260.1948,found m/z260.1954.
(R)-tert-butyldimethyl((4-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentyl)oxy)silane
[α]20 D=+4.8(c0.96,CHCl3),96.5%ee,1H NMR(CDCl3,400.1MHz):δ7.39(dd,J=8.8,7.2Hz,2H),7.37-7.32(m,2H),7.31-7.25(m,1H),3.68(t,J=6.6Hz,2H),3.02-2.91(m,1H),1.89-1.67(m,2H),1.65-1.43(m,2H),1.43-1.19(m,14H),1.02(s,9H),0.15(d,J=2.0Hz,6H);13C NMR:(100.6MHz,CDCl3):δ147.2,128.0,127.4,125.7,82.9,63.3,41.4,35.6,31.0,26.0,24.6,18.3,-5.3;11B NMR:(128MHz,CDCl3):δ33.7.
(R)-2-(2-(benzo[d][1,3]dioxol-5-yl)pentyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan e.
[α]20 D=+15.5(c1.03,CHCl3),93.9%ee,1H NMR(CDCl3,400.1MHz):δ6.73-6.67(m,2H),6.67-6.61(m,1H),5.89(s,2H),2.83-2.69(m,1H),1.56-1.46(m,2H),1.21-1.10(m,16H),0.83(t,J=7.2Hz,3H);13C NMR:(100.6MHz,CDCl3):δ147.3,145.3,141.6,120.3,107.7,107.6,100.5,82.9,41.8,41.0,24.6(2C),20.7,14.0; 11B NMR:(128MHz,CDCl3):δ33.8;HRMS(EI)calculated for[C18H27BO4]+requires m/z318.2002,found m/z318.2004.
(R)-2-((2,3-dihydro-1H-inden-1-yl)methyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborola ne.
[α]20 D=-13.0(c0.99,CHCl3),95.3%ee,1H NMR:(400.1MHz,CDCl3):δ7.26-7.07(m,4H),3.36-3.24(m,1H),2.95-2.75(m,2H),2.41-2.29(m,1H),1.70-1.55(m,1H),1.40-1.32(m,1H),1.26(d,J=4.0Hz,12H),1.02-0.92(m,1H); 13C NMR:(100.6MHz,CDCl3):δ149.1,143.7,126.0,125.9,124.2,123.3,83.1,40.7,34.8,31.4,24.9,24.7;11B NMR:(128MHz,CDCl3):δ34.2;HRMS(EI)calculated for[C16H23BO2]+requires m/z258.1791,found m/z258.1790.
(S)-4,4,5,5-tetramethyl-2-(2-methyl-4-phenylbutyl)-1,3,2-dioxaborolane.
油状液体,78%产率,[α]20 D=-3.0(c0.99,CHCl3),78.3%ee,1H NMR(400MHz,CDCl3)δ7.37–7.27(m,2H),7.22(dd,J=14.0,7.2Hz,3H),2.76–2.59(m,2H),1.92–1.76(m,1H),1.73–1.52(m,2H),1.30(s,12H),1.06(d,J=6.6Hz,3H),1.01–0.93(m,1H),0.79(dd,J=15.4,8.3Hz,1H).13CNMR(101MHz,CDCl3)δ143.23,128.43,128.31,125.56,82.93,41.66,33.89,29.48,24.97,24.91,22.39,19.87;HRMS(EI)calculated for[C17H27BO2]+requires m/z274.2104,found m/z274.2101.
油状液体,72%产率,[α]20 D=+3.3(c0.99,CHCl3),75.1%ee,1H NMR(400MHz,CDCl3)δ:1.73–1.66(m,3H),1.59(dd,J=18.1,10.2Hz,4H),1.23(bs,12H),1.20–1.03(m,4H),1.00–0.88(m,2H),0.85(d,J=6.7Hz,3H),0.81(d,J=5.0Hz,1H),0.61(dd,J=15.3,9.6Hz,1H).13C NMR(100MHz,CDCl3)δ82.79,44.81,34.53, 30.33,29.18,26.90,26.84,24.92,24.72,19.15,16.57.HRMS(EI)calculated for[C15H29BO2]+requires m/z225.2261,found m/z225.2265.
实施例2:产物氧化合成丙醇类化合物(应用实例)
(S)-2-(6-methoxynaphthalen-2-yl)propan-1-ol
在反应管中加入频那醇硼酯化合物(0.5mmol),乙醚(4mL),3mol/L的NaOH水溶液(4mL),30%的H2O2水溶液(3mL),室温搅拌2小时后用乙醚催化3次,有机相用无水硫酸钠干燥后减压蒸除溶剂,剩余的油状液体柱层析分离得到产物。(S)-(-)-2-(6-甲氧基-2萘基)-丙醇:白色固体,98%产率,1HNMR(400MHz,CDCl3)#1.35(d,J=7.2,3H),3.08(sextet,J=6.8,1H),3.77(d,J=6.8,2H),3.91(s,3H),7.12(m,2H),7.34(dd,J=2.0,8.4,1H),7.60(d,J=1.2,1H),7.70(apt.t,J=7.6,2H);13CNMR(100MHz,CDCl3)#17.6,31.6,42.4,55.3,68.7,105.6,118.9,125.9,126.3,127.2,129.0,129.1,133.6,138.6,157.5。
实施例3:产物氧化合成丙酸类药物(应用实例)
在反应管中加入由频那醇硼酯化合物氧化得到的丙醇类化合物(0.4mmol),乙腈(2mL),2mol/L的NaClO2水溶液(2mL),TEMPO(0.008mmol),PH为6.7的磷酸盐缓冲液(1.5mL),5.25%的NaClO水溶液(0.2mL).室温搅拌4小时后,在0℃加入饱和NaHCO3溶液调节反应液PH至8,再加入Na2SO3(1.4mmol)。搅拌30分钟后,加入乙酸乙酯(2mL),搅拌15分钟,移去有机相。水相加入1mol/L的HCl调节PH至2,再用乙酸乙酯萃取三次,分离得到的有机相用无水硫酸钠干燥后,减压除去溶剂得到产物。(S)-(+)-萘普生:白色固体,85%产率,[α]20 D=+63.8(c0.99,CHCl3),97.5%ee(中国药典规定药品纳普生的光学纯度必须大95%),1H NMR(CDCl3,400MHz):δ7.72(1H,s),7.69(2H,s),7.43(1H,dd,J=8.4,2.0 Hz),7.15(1H,dd,J=8.4,2.0Hz),7.11(1H,d,J=2.0Hz),3.91(3H,s),3.88(1H,q,J=7.2Hz),1.60(3H,d,J=7.2Hz);13CNMR(CDCl3,100MHz):δ181.0,157.8,134.9,133.9,129.4,129.0,127.3,126.3,126.2,119.1,105.7,55.4,45.4,18.2。
实施例4:产物合成手性氟硼化钾盐类化合物(应用实例)
反应管中加入频那醇硼酯化合物(0.5mmol),甲醇(2.5mL),4.5mol/L的KHF2水溶液(0.5mL),室温搅拌30分钟后,减压出去溶剂和水得到白色固体,加丙酮溶解,过滤除去不溶物,滤液减压除去溶剂得到产物。(S)-(+)-2-苯基丙基氟硼酸钾:白色固体,84%产率,[α]20 D=+12.8(c0.75,EtOH);96.1%ee,1H NMR(CD3CN,400MHz):δ7.24-7.18(m,4H),7.09-7.04(m,1H),2.82-2.72(m,1H),1.17(d,J=6.8Hz,3H),0.45-0.43(m,2H);13C NMR(CD3CN,100.6MHz):δ154.5,128.6,127.3,125.2,37.6,24.9,-0.3;19F NMR(CD3CN,128MHz):δ132.8(br,s)。
实施例5:产物合成手性二级胺类化合物(应用实例)
反应管中频那醇硼酯化合物(0.5mmol),滴加1mol/L的BCl3的二氯甲烷溶液,室温搅拌4小时后,减压抽干溶剂,在0℃加入二氯甲烷(3mL),苄基叠氮(1.5mmol),室温反应12小时后加入2mol/L的NaOH水溶液和乙醚,分液萃取3次,有机相用无水硫酸钠干燥后,减压除去溶剂,剩余的油状液体柱层析分离得到产物。(R)-(+)-N-苄基-2-苯基丙胺:油状液体,93%产率,[α]20 D=+15.8(c1.0,CHCl3);96.1%ee;1H NMR(CDCl3,400MHz):δ7.32-7.27(m,4H),7.25-7.19(m,6H),3.80-3.71(m,2H),3.01-2.92(m,1H),2.79(d,J=7.6Hz,2H),1.47(br,1H),1.25(d,J=6.8Hz,3H);13C NMR:(100.6MHz,CDCl3):δ145.3,140.3,128.5,128.3,128.0,127.2,126.8,126.3,56.3,53.8,40.0, 20.1;HRMS(EI)calculated for[C16H19N]+requires m/z225.1517,found m/z225.1516.
以上列举的仅是本发明的一些具体实施例,显然,本发明不限于以上实施例,还可以有许多变形,本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
Claims (8)
1.一种合成手性频那醇硼酯化合物的方法,其特征是,以烯烃和频那醇硼烷为原料,以手性FeX2-IPO络合物为催化剂,在三乙基硼氢化钠存在下,反应3分钟-48小时制得频那醇硼酯化合物,所述的烯烃、频那醇硼烷、FeX2-IPO络合物、三乙基硼氢化钠的摩尔比为1:0.1-10:0.0005-0.05:0.0015-0.15;
所述的烯烃的结构式为R1≠R2;
所述的频那醇硼烷的结构式为
其中,R1,R2任选自包括环烷基在内的C1-C16的烷基、取代的芳基其中R3,R4,R5,R6,R7任选自H、卤素、C1-C16的烷基、C1-C16的烃氧基,烃硫基中的任意一种,X为F、Cl、Br、I、OAc、CF3SO3中的任意一种。
2.根据权利要求1所述的合成频那醇硼酯化合物的方法,其特征是,所述的FeX2-IPO络合物为手性络合物,所述的产物频那醇硼酯化合物为光学活性的,其结构式为其中*代表手性碳原子R1,R2任选自包括环烷基在内的C1-C16的烷基、取代的芳基
3.根据权利要求1或2所述的合成频那醇硼酯化合物的方法,其特征是,所述的FeX2-IPO络合物的结构式为光学纯的如下化合物或其对映体或消旋体,R8任选自C1-C16的烃基、萘基、取代的芳基,苄基:
X为F、Cl、Br、I、OAc、CF3SO3中的任意一种。
4.根据权利要求1所述的合成频那醇硼酯化合物的方法,其特征是,所述合成方法中有有机溶剂的参与,所述的有机溶剂是苯、四氯化碳、甲苯、四氢呋喃、乙醚、二氯甲烷、乙腈、二氧六环、石油醚、环己烷、正己烷、乙酸乙酯、三氯甲烷、N,N-二甲酰胺中的任意一种。
5.根据权利要求1所述的合成频那醇硼酯化合物的方法,其特征是,所述合成方法中不加任何溶剂。
6.根据权利要求1或2或4或5所述的合成频那醇硼酯化合物的方法,其特征是,所述的烯烃、频那醇硼烷、FeX2-IPO络合物、三乙基硼氢化钠的摩尔比为1:0.5-2:0.005-0.05:0.015-0.15。
7.根据权利要求1或2或4或5所述的合成频那醇硼酯化合物的方法,其特征是,所述合成方法中,反应温度为-30℃~80℃。
8.根据权利要求7所述的合成频那醇硼酯化合物的方法,其特征是,所得的产物是经过重结晶、薄层层析、柱层析或减压蒸馏加以分离而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410566747.3A CN104402919A (zh) | 2014-10-22 | 2014-10-22 | 一种合成手性频那醇硼酯化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410566747.3A CN104402919A (zh) | 2014-10-22 | 2014-10-22 | 一种合成手性频那醇硼酯化合物的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104402919A true CN104402919A (zh) | 2015-03-11 |
Family
ID=52640598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410566747.3A Pending CN104402919A (zh) | 2014-10-22 | 2014-10-22 | 一种合成手性频那醇硼酯化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104402919A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110372633A (zh) * | 2019-08-01 | 2019-10-25 | 台州学院 | 一种催化亚氨基二苄碳基衍生物还原的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103071533A (zh) * | 2013-02-04 | 2013-05-01 | 中国科学院上海有机化学研究所 | 一种pnn配体-铁络合物催化剂及其制备方法和应用 |
-
2014
- 2014-10-22 CN CN201410566747.3A patent/CN104402919A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103071533A (zh) * | 2013-02-04 | 2013-05-01 | 中国科学院上海有机化学研究所 | 一种pnn配体-铁络合物催化剂及其制备方法和应用 |
CN103962183A (zh) * | 2013-02-04 | 2014-08-06 | 中国科学院上海有机化学研究所 | 一种pnn配体-金属络合物催化剂及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
LEI ZHANG, ET AL.: "A Cobalt-Catalyzed Alkene Hydroboration with Pinacolborane", 《ANGEW. CHEM. INT. ED.》 * |
LEI ZHANG, ET AL.: "Cobalt-Catalyzed Enantioselective Hydroboration of 1,1- Disubstituted Aryl Alkenes", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》 * |
LEI ZHANG,ET AL.: "Iron-Catalyzed, Atom-Economical, Chemo- and Regioselective Alkene Hydroboration with Pinacolborane", 《ANGEW. CHEM. INT. ED.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110372633A (zh) * | 2019-08-01 | 2019-10-25 | 台州学院 | 一种催化亚氨基二苄碳基衍生物还原的方法 |
CN110372633B (zh) * | 2019-08-01 | 2022-11-04 | 台州学院 | 一种催化亚氨基二苄碳基衍生物还原的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guilbault et al. | Catalytic enantioselective α-tosyloxylation of ketones using iodoaryloxazoline catalysts: insights on the stereoinduction process | |
Tsuji et al. | Indium-catalyzed cycloisomerization of ω-alkynyl-β-ketoesters into six-to fifteen-membered rings | |
Jalalian et al. | Design and asymmetric synthesis of chiral diaryliodonium salts | |
JP6157358B2 (ja) | 有機亜鉛錯体ならびに有機亜鉛錯体を作製および使用するための方法 | |
Khan et al. | Synthesis of new ionic-liquid-tagged organocatalysts and their application in stereoselective direct aldol reactions | |
Nelson et al. | Chemo-, regio-, and stereoselective copper (II)-catalyzed boron addition to acetylenic esters and amides in aqueous media | |
CN109718851B (zh) | 一种手性季鏻盐相转移催化剂及其制备方法和应用 | |
Sekine et al. | Enantioselective Functionalization of Difluorocyclopropenes Catalyzed by Chiral Copper Complexes: Proposal for Chiral gem-Dimethyl and tert-Butyl Analogues | |
US10072028B2 (en) | Cross-coupling of unactivated secondary boronic acids | |
KR20010081106A (ko) | 하이드로보로네이션 방법 | |
WO2014066772A1 (en) | Processes and reagents for making diaryliodonium salts | |
Yuan et al. | Bi (cyclopentyl) diol-derived boronates in highly enantioselective chiral phosphoric acid-catalyzed allylation, propargylation, and crotylation of aldehydes | |
US9278959B2 (en) | Processes and reagents for making diaryliodonium salts | |
JP5417560B2 (ja) | 光学活性カルボン酸エステルを製造する方法 | |
CN104402919A (zh) | 一种合成手性频那醇硼酯化合物的方法 | |
Paramanik et al. | Catalytic nucleophilic fluorination by an imidazolium ionic liquid possessing trialkylphosphine oxide functionality | |
CN104603142A (zh) | 烯烃和炔烃中间体的β-硼化 | |
Zhang et al. | Investigation of catalytic activity and catalytic mechanism of chiral amino diol tridentate ligands in the asymmetric addition of aldehydes in the present of methyllithium reagent | |
CN104860975B (zh) | 一种硼替佐米合成中间体的制备方法 | |
Lee et al. | Enantioselective conjugate radical addition to α′-phenylsulfonyl enones | |
Harada et al. | Improvement of the asymmetry-inducing ability of a trifluoromethylated amino alcohol by electron donation to a CF3 group | |
CN108373431A (zh) | 含氟手性烯丙基化合物及其合成方法 | |
Shan et al. | Selective 1, 3-cycloboronation of enantiopure 1, 1, 4, 4-tetrasubstituted butanetetraols: versatile preparation, structural characterization, and properties of chiral cyclic boron-containing bifunctional Lewis acids | |
Ng | Zwitterion-Catalyzed Organic Transformations and Ammonium Fluoride-Catalyzed Dibromination of Alkenes | |
CN104114530B (zh) | 羟基羧酸酰胺化合物的制法和新型的芳基硼酸化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150311 |